Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine
Open accessThe DOI matches its Crossref record.
Abstract
Chronic lung infection with mucoid Pseudomonas aeruginosa is the major pathologic feature of cystic fibrosis. Previous studies suggested that a failure to produce opsonic antibody to the mucoid exopolysaccharide (MEP; also called alginate) capsule is associated with the maintenance of chronic bacterial infection. Provision of MEP-specific opsonic antibodies has therapeutic potential. To evaluate the ability of MEP to elicit opsonic antibodies, humans were immunized with two lots of MEP vaccine that differed principally in molecular size. Lot 2 had a larger average MEP polymer size. Both vaccines were well tolerated, but lot 1 was poorly immunogenic, inducing long-lived opsonic antibodies in only 2 of 28 vaccinates given doses of 10 to 150 micrograms. In contrast, at the optimal dose of 100 micrograms, lot 2 elicited long-lived opsonic antibodies in 80 to 90% of the vaccinates. The antibodies elicited by both lots enhanced deposition of C3 onto mucoid P. aeruginosa cells and mediated opsonic killing of heterologous mucoid strains expressing distinct MEP antigens. These results indicate that the polymers of MEP with the largest molecular sizes safely elicit opsonic antibodies in a sufficiently large proportion of vaccinates to permit studies of active and passive immunization of cystic fibrosis patients against infection with mucoid P. aeruginosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia
Govan, J. R. W., & Deretic, V. P. (1996) · Microbiological Reviews · doi:10.1128/mmbr.60.3.539-574.1996 · Cited by 1,812
Lung Infections Associated with Cystic Fibrosis
Lyczak, J. B., Cannon, C. L., & Pier, G. B. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.194-222.2002 · Cited by 1,628
Self-citationThe role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Ramsey, D. M., & Wozniak, D. J. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04552.x · Cited by 391
Targeting mechanisms of Pseudomonas aeruginosa pathogenesis
Kipnis, E., Sawa, T., & Wiener-Kronish, J. (2006) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2005.10.007 · Cited by 353
Metadata
- Authors
- Pier, G. B., DesJardin, D., Grout, M., Garner, C., Bennett, S. E., Pekoe, G., Fuller, S. A., Thornton, M. O., Harkonen, W. S., & Miller, H. C.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 1994-09
- Volume
- 62
- Issue
- 9
- Pages
- 3972-3979
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2100757485
- Cited by
- 84
- References
- 0
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. https://app.cochat.ai/papers/10.1128/iai.62.9.3972-3979.1994
- The paper
- Pier, G. B., DesJardin, D., Grout, M., Garner, C., Bennett, S. E., Pekoe, G., Fuller, S. A., Thornton, M. O., Harkonen, W. S., & Miller, H. C. (1994). Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infection and Immunity. https://doi.org/10.1128/iai.62.9.3972-3979.1994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.